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Abstract
Background: Prognostic factors in patients who are diagnosed with T4 breast carcinomas are widely awaited. We
here evaluated the clinical role of some molecular alterations involved in tumorigenesis in a well-characterized
cohort of T4 breast cancer patients with a long follow-up period.
Methods: A consecutive series of 53 patients with T4 breast carcinoma was enrolled between 1992 and 2001 in
Sardinia, and observed up for a median of 125 months. Archival paraffin-embedded tissue sections were used for
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses, in order to assess alterations in
expression levels of survivin, p53, and pERK1-2 proteins as well as in amplification of CyclinD1 and h-prune genes.
The Kaplan-Meier and Cox regression methods were used for survival assessment and statistical analysis.
Results: Overall, patients carrying increased expression of pERK1-2 (p = 0.027) and survivin (p = 0.008) proteins as
well as amplification of h-prune gene (p = 0.045) presented a statistically-significant poorer overall survival in
comparison with cases found negative for such alterations. After multivariate analysis, the pathological response to
primary chemotherapy and the survivin overexpression in primary carcinoma represented the main parameters
with a role as independent prognostic factors in our series.
Conclusions: Although retrospective, our study identified some molecular parameters with a significant impact on
prediction of the response to therapy or prognosis among T4 breast cancer patients. Further large prospective
studies are needed in order to validate the use of such markers for the management of these patients.
Background
Since the staging systems of breast cancer were intro-
duced during the course of the last century, the invol-
vement of the skin has always been considered a
morphologic characteristic leading to the classification
of the tumour into the highest non-metastatic disease
stage. In the current edition of the International Union
Against Cancer (UICC)/American Joint Committee on
Cancer (AJCC) TNM staging system [1], primary
breast cancers with extension to the skin are classified
as T4. Patients with T4 carcinomas of any type, with
or without lymph node involvement, and without dis-
tant metastases (T4 N0-2 M0), are classified as disease
stage IIIB. According to this system, the breast carci-
noma with skin involvement is included in stage III
and may be considered as locally-advanced breast
cancer (LABC) [1-3].
In addition to the tumour size and the axillary lymph
node involvement, other well-established prognostic fac-
tors currently used in breast cancer include histological
subtype or grade, estrogen (ER) and progesterone (PR)
receptor status, HER2 amplification, and Ki67 prolifera-
tion index [4,5]. Novel tumour markers with potential
clinical utility are thus awaited.
The molecular mechanisms underlying locally-
advanced breast carcinomas are largely unknown. A dis-
tinct gene-expression profile has been described for T3/
T4 tumours in comparison to the gene-expression pat-
tern of T1/T2 tumours [6], suggesting that a distinct
biological behaviour may characterize initial vs. locally-
advanced breast carcinomas. The mitogen activated pro-
tein kinase (MAPK) pathway, a major signalling cascade
involved in the control of cell growth and proliferation,
has been indicated to play a role in the intracellular
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2 proteins, which represent the final components of
such a signalling kinase cascade, have been found to be
activated through phosphorilation (pERK1-2)i nh u m a n
cancer and implicated in rapid malignant cell growth,
mostly as a consequence of mutations in upstream com-
ponents of the pathway [10,11]. Presence of pERK1-2
c o u l db et h u sc o n s i d e r e da sam a r k e rf o rt h ei n c r e a s e d
activity of ERK1-2, which may induce cell proliferation,
rapid cancer cell growth, and resistance to apoptosis
[10]. Moreover, a genomic instability with an increased
number of copies of the CyclinD1 gene, which encodes
a component of the p16
CDKN2A-RB pathway functionally
interacting with the MAPK pathway [12,13], has been
described to promote a deregulation of the cell cycle
with subsequent induction of an uncontrolled cell prolif-
eration and tumour growth [14]. Nevertheless, the p53
protein represent the final effector of the p14
CDKN2A-
MDM2 pathway; in majority of human cancers, the
TP53 gene is functionally inactivated [15]. Lack or
reduced expression levels of the p53 protein seems to
be associated with a defective apoptotic response to gen-
otoxic damage and, thus, to anticancer agents [16].
Finally, two additional mechanisms seem to play a
central role in breast cancer progression and resistance
to treatment. The increased expression of survivin, a
member of the inhibitor-of-apoptosis (IAP) protein
family, has been demonstrated to be associated with
resistance to apoptosis [17-19]. It has been reported that
survivin and other IAP proteins cooperate to activate
kinase cascades which control cell motility, thus stimu-
lating tumour cell invasion and promoting metastasis
[19]. Survivin is indeed overexpressed in most cancer
cells and tissues of different histological origin, being
correlated to overall survival and acting as a poor prog-
nostic factor in some cancer patients [20-22]. In breast
carcinomas, the up-regulation of survivin has been
hypothesized to act as a factor exerting resistance
against tamoxifen-induced apoptosis [23,24]. The second
additional mechanism involved in breast cancer patho-
genesis includes an increased activity of the human
homologue of the Drosophila prune (h-prune), which
belongs to a superfamily of phosphoesterases [25]. It has
been demonstrated that h-prune is able to promote cell
motility through either induction of its phosphodiester-
ase activity (very recently, a multi-domain adaptor pro-
tein, ASAP1, has been reported to stimulate the h-prune
phosphodiesterase activity [26]) or interaction with spe-
cific protein partners (mainly, nm23-H1) [27-29]. The
h-prune protein has been found expressed at higher
levels in breast, colorectal, and gastric carcinomas, parti-
cipating to the promotion of both tumour invasiveness
and metastasis formation [25,27]. In breast cancer, over-
expression of h-prune has been demonstrated to be
involved in cancer progression, identifying subsets of
patients with higher tumour aggressiveness (although it
seems to have no role as independent prognostic factor
in clinical outcome of patients with invasive breast car-
cinoma) [30]. As previously demonstrated [25,30], gene
amplification may play an important role in inducing
overexpression of h-prune among breast cancer patients.
In the present study, we examined the expression of
survivin, p53, and pERK1-2 proteins as well as the ampli-
fication of CyclinD1 and h-prune genes in a well-charac-
terized cohorts of patients with T4 breast carcinoma
and a long follow-up, in order to determine their asso-
ciation with clinical and pathological parameters as well
as with patients’ outcome.
Methods
Cases and tissue samples
Paraffin-embedded samples of 53 consecutive patients
with T4 breast cancer were included into the study.
Cases were enrolled between 1992 and 2001, and
observed up to September 2008 for a median of 125
months (range, 82-194). Patients were assessed by physi-
cal examination and mammography, confirmed via core-
needle biopsy. All patients completed a treatment plan
including primary chemotherapy, surgery, radiation ther-
apy, adjuvant chemotherapy, and hormone therapy,
when indicated (see below). The median age was 51
Table 1 Patient and tumour characteristics at baseline
Characteristics Patients
N%
Age
<50 23 43
>50 30 57
Tumor stage
T4abc 38 72
T4d 15 28
Axillary lymph nodes
N0 0 0
N+ 53 100
Hormone receptor status
ER+/ER- 28/25 53/47
PR+/PR- 17/36 32/68
Proliferative index
Ki67+ 17 32
Ki67- 27 51
unknown 9 17
Tumour Grading
G2/G3 38/15 72/28
HER2 status
HER2+ 10 19
HER2- 43 81
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marized in Table 1.
Fifteen patients (28%) had initially inflammatory breast
carcinoma (T4d) and 38 (72%) had initially non-inflam-
matory cancer (T4abc); all patients had clinical involve-
ment of axillary limph nodes (as N+). According to the
American Joint Committee on Cancer (AJCC) TNM sta-
ging system [1], all 53 cases included into this study
were classified with the highest stage of non-metastatic
disease (Stage IIIB). Estrogen (ER) and progesterone
(PR) status was assessed by standard immunohistochem-
istry; nuclear staining in ≥10% was considered positive
(according to the indication that a significant difference
in 5-year recurrence-free survival between ER-positive
and ER-negative patients has been reported for a cut-off
of 10% [31]). HER2 status was assessed by fluorescence
in situ hybridization (FISH) analysis.
The study was approved by the Institutional Review
Board at the University of Cagliari. A written informed
consent was obtained for using tissue specimens in
molecular analyses.
Treatment plan
All patients were treated with primary chemotherapy
using anthracyline-containing regimens, such as FEC (5-
Fluorouracil; Epirubicin; Cyclophosphamide) or PEV
(Cisplatin; Epirubicin; Vinorelbine). After completing
the neoadjuvant chemotherapy, patients underwent sur-
gery consisting of modified radical mastectomy (MRM)
or breast-conserving surgery (BCT). Postoperative adju-
vant chemotherapy consisted of six cycles of CMF
(cyclophosphamide, methotrexate, fluorouracil). Locore-
gional radiotherapy was performed during the fourth
course of CMF. After completing adjuvant chemother-
apy, patients with hormone receptor-positive tumours
received tamoxifen for 5 years.
Clinical evaluations were performed every 3 months
for 2 years and every 6 months thereafter. Instrumental
examinations (e.g., mammography, liver ultrasound,
chest X-ray, bone scan, and echocardiogram) were per-
formed every 6 months for the first 2 years, and every
12 months thereafter.
Response Assessment
The clinical measurement of the response to neoadju-
vant therapy was defined according to the International
Union Against Cancer (UICC) criteria [32]. Pathological
complete response (pCR) was defined as the histological
absence of residual invasive disease in both the breast
and the axilla. Presence of histological invasive residual
disease in breast tissue or detection of cancer-positive
lymph nodes in the axilla were defined as <pCR. Major
pathological response (MpR) in breast tissue was defined
as no more than 2 cm of residual disease (pT0 plus
pT1) [27].
Immunohistochemistry (IHC)
Immunohistochemical staining was done on formalin-
fixed, paraffin-embedded sections, as previously
described [30]. Four- to five-micrometer sections were
immunostained with each specific monoclonal antibody
(anti-survivin, anti-p53, and anti-phosphorilated ERK1-2).
Slides were viewed using a BX61 Olympus Microscope
supplied with DP50 camera and Viewfinder Lite 1.0
Version (Pixera Corporation) image analysis system.
Labelling intensity and cellular staining was indepen-
dently evaluated by two observers. Intensity and distri-
bution of IHC staining was used to classify samples as
positive (tissue sections presenting strong to moderate
staining in more than 10% of cells) or negative (includ-
ing tissue sections showing weak to absent staining) for
expression of candidate genes.
Fluorescence in situ Hybridization (FISH)
For h-prune and CyclinD1 gene amplification analysis,
double-colour FISH analysis was performed using the
PAC 279-H19 clone, spanning the h-prune gene region
at chromosome 1q21, and the BAC RP11-300I6 clone
specific for the CyclinD1 gene at chromosome 11q13,
according to previously reported protocols [25,30].
Nuclei were counterstained with 4’,6-diamidino-2-phe-
nyl-indole (DAPI). Three distinct experiments were per-
formed for each case. Digital images were captured
using an Olympus BX-61 epifluorescence microscope,
e q u i p p e dw i t ht h ea p p r o p r i a t ef i l t e r s ,aC O H Uv i d e o ,
and the Cytovision software.
Hybridization signals on at least 100 intact, well-pre-
served, and non-overlapping nuclei were evaluated by at
least two investigators. A gain of gene copy was defined
as presence of multiple (three or more) signals in at
least 10% of nuclei
Statistical analysis
Chi-square and Fisher’s exact tests were used to evaluate
possible associations between covariates (ER; PR; Ki67
proliferative index; HER2; expression for survivin, p53,
and phosphorilated ERK1-2; amplification of h-prune
and Cyclind1) and clinical outcome in terms of treat-
ment responses and median survivals. Univariate corre-
lations between prognostic variables and survival
outcomes were carried out using the Kaplan-Meier
method. Variables were also evaluated for independent
correlations on survival by Cox regression analysis. Sta-
tistical comparisons were performed using the SPSS sta-
tistical software package, version 15.0 (SPSS Inc.,
Chicago, IL, USA). All tests were two-tailed and
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cally significant.
Results
Patients’ collection
To evaluate the pathogenetic and prognostic roles of
five candidate molecular markers (expression levels of
survivin, p53, and pERK1-2 proteins; amplification of
CyclinD1 and h-prune genes), we have examined fifty-
three patients with diagnosis of T4 breast carcinoma
(T4-N0-2-M0, according to the TNM classification by
Sobin et al. [1]).
All patients were evaluated for response to primary
chemotherapy. No disease progression was observed
during the treatment. The clinical response rate was
100% (95% CI, 65,2-89,5): a complete clinical response
was observed in 8 patients (15%). According to Sataloff’s
classification [33], pathological complete response in pri-
mary tumour (pCR) was observed in 8 patients (15%);
major pathological response (MpR), corresponding to
pT0-pT1 classification after primary chemotherapy, was
observed in 18 (34%) breast tissues. The pathological
lymph node assessment revealed absence of involvement
(pN0) in 12 (23%) patients after primary chemotherapy.
All 53 patients became suitable for surgery. Modified
radical mastectomy was performed in 36 patients (68%)
and breast conserving treatment (BCT) was feasible in
17 patients (32%). Records of the clinical follow-up cov-
ered a median period of 125 months (range 70-182); 10-
year disease-free survival (DFS) and overall survival (OS)
within the entire series were 32% and 43%, respectively.
Immunohistochemistry and FISH analysis
Assessment of the expression levels of survivin, p53, and
pERK1-2 proteins by immunohistochemistry (IHC) as
well as characterization of the chromosomal copy num-
ber of cyclinD1 and h-prune genes by fluorescence in
situ hybridization (FISH) analysis was carried out on
paraffin-embedded tissue sections from primary breast
carcinomas of our series.
For IHC analysis, a lack of expression for the p53 pro-
tein was observed in 13/53 (25%) patients; conversely, a
positive immunostaining was detected in 5/53 (9%)
cases for pERK1-2, and 21/53 (40%) cases for survivin
(Table 2). The FISH analysis was performed using speci-
fic probes corresponding to the h-prune and cyclinD1
genomic regions at chromosomes 1q21 and 11q13
(respectively) as well as control clones spanning the
peri-centromeric regions at chromosomes 1 and 11,
respectively. Multiple FISH signals in >10% analyzed
nuclei were found in 8/53 (15%) cases, for h-prune,a n d
12/53 (23%) cases, for cyclinD1 (Table 2). A normal
copy number (diploid signals) was detected for centro-
meric control probes, confirming the specificity of the
amplification at 1q21 and 11q13 loci and excluding any
procedure artifact. Absence of karyotypic anomalies in
cells from normal tissues surrounding the tumours
strongly indicated that amplification of the h-prune and
cyclinD1 genomic regions was highly specific for breast
cancer cells. Representative examples of IHC staining
and FISH results are shown in Figure 1.
Correlation with clinico-pathological parameters
Using Pearson’s Chi-Squared test, molecular alterations
were evaluated for association with histological tumour
characteristics: ER and PR status, HER2 amplification,
Ki67 proliferation index. No statistically significant cor-
relation between any of the molecular alteration and
pathological parameters was observed (including triple
negative tumours: ER-, PR-, HER2-), with the exception
of the detection of positive pERK1-2 immunostaining in
the group of patients negative for Ki67 expression only
[the pERK1-2 expression was not detected in tumours
expressing Ki67 (0/16), whereas 4/26 (15%) Ki67+
tumours presented a positive pERK1-2 immunostaining;
p = 0.041] (Table 2).
To investigate the role in predicting the response to
primary chemotherapy, all tumour characteristics (histo-
logical parameters and molecular alterations) were com-
pared to clinical and pathological outcome in our series.
As shown in Table 3, the Ki67 proliferation index and
HER2 amplification were significantly associated with a
better clinical outcome [5/7 (71%) complete clinical
responses vs. 11/35 (31%) partial clinical responses, for
Ki67 proliferation index; 8/8 (100%) complete clinical
responses vs. 29/45 (64%) partial clinical responses, for
HER2 amplification]. Conversely, the expression of
pERK1-2 was significantly associated with a worse clini-
cal outcome [0/8 complete clinical response vs.5 / 4 5
(11%) partial clinical responses] (Table 3). Considering
the histological classification, a higher prevalence of
positive Ki67 proliferation index was found in cases
achieving the pathological response [5/7 (71%) pCR vs.
11/35 (31%) non-pCR]; a positive pERK1-2 expression
was instead observed in patients who did not achieve
the pathological response [0/8 pCR vs. 5/45 (11%) non-
pCR] (Table 3).
Each molecular alteration was then evaluated for its
impact on overall survival. Using the Kaplan-Meier
method, survival curves indicated that patients carrying
pERK1-2 positive staining (p = 0.027), h-prune amplifica-
tion (p = 0.045), and survivin overexpression (p = 0.008)
presented a statistically-significant poorer overall survi-
val in comparison with those resulted negative for such
alterations (Figure 2A). No significant association with
overall survival was observed for p53 down-expression
and cyclinD1 amplification (Figure 2A). As summarized
in Figure 2B, median overall survivals were consistently
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amplification (median OS: 96 months in comparison to
59 months of patients with h-prune polysomy) and
negative immunostaining for pERK1-2 (median OS: 95
months in comparison to 43 months of patients with
pERK1-2+ tumours) and survivin (median OS: 97
months in comparison to 45 months of patients with
survivin overexpression).
Using the Cox model adjusted according to age at
diagnosis for a multivariate analysis, pathological
response to primary chemotherapy and survivin overex-
pression remained the only parameters with a significant
impact on prognosis in our series of breast cancer
patients; no other association with overall survival was
observed for the remaining variables (Table 4).
Discussion
In this study, we evaluated the impact of some specific
molecular alterations (activation of ERK1-2 proteins,
amplification of CyclinD1 and h-prune genes, silencing
of TP53 gene, overexpression of survivin protein) as pre-
dictive and prognostic factors among patients with T4
breast carcinoma. The analyzed molecular alterations
have been largely demonstrated to play an important
role in: a) deregulating the cell cycle with subsequent
induction of abnormal cell proliferation and tumour
growth (ERK1-2 phosphorilation and CyclinD1 amplifi-
cation); b) impairing the apoptotic machinery with sub-
sequent induction of resistance to anticancer agents
(p53 downexpression and survivin overexpression); and
c) promoting metastasis formation (h-prune amplifica-
tion). Our findings indicated that subsets of T4 breast
cancer patients with pERK1-2 staining, survivin expres-
sion, or h-prune amplification in primary tumour tissues
presented a worse overall survival. After multivariate
analysis, the pathological response to primary che-
motherapy and the survivin overexpression in primary
carcinoma represented the main parameters with a role
as independent prognostic factors predicting the clinical
outcome in such a series of breast cancer patients.
Although an increased expression of survivin in
tumour tissues has been already demonstrated to corre-
late with a poor clinical outcome in a variety of malig-
nancies [20-22], our results clearly indicated an
analogous significant impact on prognosis of such a
molecular alteration among T4 breast cancer patients.
From the pathogenetic point of view, survivin has been
found to provide protection against apoptotic stimuli by
inhibiting activation of caspase-9 toward the initiation of
the intrinsic mitochondrial pathway of apoptosis [18].
Recently, it has been demonstrated that survivin as well
as other members of the IAP protein family are strongly
involved in metastasis formation; search for survivin-
IAP antagonists may indeed provide new antimetastatic
therapies for cancer patients [19]. Nevertheless, survivin
seems to be upregulated through the activation of the
MAPK-ERK pathway [34]; in other words, the overex-
pression of survivin may be associated with the
increased levels of ERK1-2 phosphorylation (in our ser-
ies, all 5 cases expressing pERK1-2 proteins also pre-
sented survivin overexpression). Interestingly, our
findings indicated that presence of pERK1-2 expression
in primary T4 carcinomas may be indeed correlated
with clinical outcome (see Figure 2), suggesting that the
cascade of molecular events activating ERK1-2 and
upregulating survivin has indeed an important prognos-
tic role in such patients. One could speculate that the
lack of a significant association with prognosis for
Table 2 Comparison between IHC or FISH results and histopathological parameters
Characteristics FISH analysis IHC analysis
CyclinD1 h-prune p53 pERK1-2 survivin
positive cases % positive cases % positive cases % positive cases % positive cases %
Total patients (N = 53) 12 23 8 15 13 25 5 9 21 40
Estrogen receptor (ER)
negative (N = 20) 2 10 1 5 4 20 2 10 9 45
positive (N = 24) 7 29 5 11 5 21 2 8 7 29
Progesterone receptor (PR)
negative (N = 28) 5 18 2 7 5 18 2 7 13 46
positive (N = 16) 4 25 4 25 4 25 2 12 3 19
Ki67
negative (N = 26) 4 15 3 12 4 15 4 15 11 42
positive (N = 16) 4 25 2 12 5 31 0 0 5 31
HER2
0-1 (N = 16) 5 31 3 19 2 12 2 12 9 56
2-3 (N = 37) 7 19 5 14 11 30 3 8 12 32
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Page 5 of 10Figure 1 Immunohistochemistry and FISH analysis. (Up-middle) Typical examples of T4 breast carcinoma tissue sections positive (left) or
negative (right) for p53, pERK1-2, and survivin protein expression. (Bottom) Typical examples of double-colour FISH results. Nuclei extracted from
paraffin-embedded tissues after hybridization with probes specific for cyclinD1 or h-prune loci (red signals) and control chromosome centromeres
(green signals).
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the fact that we identified only a limited fraction (5/53;
9%) of carriers and, thus, the subgroup analysis relied
on a small number of subjects.
The well-established prognostic factors currently used
into the management of breast cancer patients include
the disease stage as well as the degree of differentiation
(tumour grade), the proliferation index, and the hor-
mone receptor status (ER, PR, and, recently, HER2) in
primary tumours [35,36]. In our series of patients with
T4 breast carcinoma, no statistically-significant correla-
tion between any of the analyzed molecular alterations
and such pathological parameters was inferred. The only
exception was represented by the correlation between
the pERK1-2 staining and the Ki67 proliferation index.
None of the tumours expressing a high Ki67 prolifera-
tion index showed an increased level of pERK1-2 protein;
conversely, all cases with activated ERK1-2 protein pre-
sented a low Ki67 proliferation index. Activation of
ERK1-2 proteins has been demonstrated to promote cell
cycle progression, participating to induction of cell
growth and enhancement of cell survival [10]. Our find-
ings led us to speculate that: a) induction of cell prolif-
eration via pERK1-2 and Ki67 molecules may represent
two unrelated phenomena; and b) among patients with
low Ki67 expression levels (who may have an unfavour-
able prognosis [37], though the role of Ki67 proliferation
index as prognostic and predictive marker is yet to be
conclusively defined [38]), the presence of pERK1-2 over-
expression seems to identify a subgroup with an even
worse prognosis. Taking into consideration the response
rates, patients whose tumours had high Ki67 expression
levels or HER2 amplification presented the highest rates
of response to primary chemotherapy (for Ki67, a signif-
icant association was found with both clinical and
pathological responses; for HER2, a significant associa-
tion was surprisingly observed with clinical response
only) (see Table 3). These latter findings are consistent
with data previously reported [39-41]. Among the mole-
cular parameters, only pERK1-2 expression seemed to be
significantly correlated with response to primary che-
motherapy (significant lower rates were observed for
both clinical and pathological responses; see Table 3),
reflecting the fact that the activation of ERK1-2 proteins
may increase the resistance to apoptosis, reducing the
sensitivity to chemotherapy [10].
Several mechanisms have been recently described to
participate in progression of breast cancer through acti-
vation of the h-prune complex. It is now clear the exis-
tence of a network of interacting proteins which indeed
regulate the phosphodiesterase activity of h-prune, con-
tributing to promote (ASAP1) or inhibit (nm23-H1)
either cancer cell motility and tumour adhesiveness in
vitro either tumour invasiveness and metastasis forma-
tion in vivo [25-29]. The increased expression of h-
prune protein has been demonstrated to deeply modify
this equilibrium of opposite stimuli, playing an impor-
tant role in promotion of cancer progression [25].
Among others, the main mechanism leading to h-prune
overexpression is represented by the amplification of
Table 3 Comparison between histopathological or molecular parameters and response to therapy
A
Outcome ER PR Ki67 HER2
positives % P positives % P positives % P positives % P
Clinical response 0.132 0.640 0.047 0.022
Complete response 3/7 43 3/7 43 5/7 71 8/8 100
Partial response 16/29 55 11/29 38 9/27 33 27/37 73
< Partial response 5/8 62 2/8 25 2/8 25 2/8 25
Pathological response 0.469 0.235 0.042 0.095
pCR 4/7 57 3/7 43 5/7 71 7/8 87
<pCR 20/37 54 13/37 35 11/35 31 30/45 67
B
Outcome cyclinD1 h-prune pERK1-2 p53 survivin
positives % P positives % P positives % P positives % P
Clinical response 0.457 0.824 0.032 0.391 0.089
Complete response 1/8 12 1/8 12 0/8 0 1/8 12 1/8 12
Partial response 8/37 22 5/37 14 3/37 8 10/37 27 15/37 41
< Partial response 3/8 37 2/8 25 2/8 25 2/8 25 5/8 62
Pathological response 0.660 0.822 0.007 0.972 0.234
pCR 2/8 25 1/8 12 0/8 0 2/8 25 3/8 37
<pCR 10/45 22 7/45 16 5/45 11 11/45 24 18/45 40
pCR, pathological complete response
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least three gene copies, a small fraction (8/53; 15%) of
T4 breast carcinomas from our series presented h-prune
amplification at chromosome 1q21.3 (see Table 2); such
a frequency is quite identical to that described in our
previous report (173/1,016; 17%) [30]. All breast cancer
patients included into the present study showed axillary
nodal involvement; among them, occurrence of h-prune
amplification was able to identify a subset with a worse
overall survival (see Figure 2). As for pERK1-2 staining,
the low number of events could explain the absence of a
significant association of the h-prune amplification with
prognosis in the multivariate analysis.
Conclusions
Although our study was retrospective, some important
indications about either the prediction of the response
to therapy or the role on prognosis in T4 breast cancer
patients have been inferred. There is no doubt that the
pathological response after primary chemotherapy
remains one of the major predictor of survival; however,
the molecular marker represented by survivin overex-
pression may be also considered as a useful prognostic
factor in these patients. To validate the incorporation of
survivin or the other promising molecular parameters
Figure 2 Comparison between molecular markers and survivals among T4 breast cancer patients. (A) Overall survival curves based on the
Kaplan-Meier method. Statistical comparison between observed and predicted survival data for each subset of patients [with (+) or without (-)
alterations in expression of p53, pERK1-2 and survivin proteins or in copy number of h-prune and cyclinD1 genes) is reported. (B) Median disease-
free and overall survivals (DFS and OS, respectively), expressed in months, for each subset of patients.
Table 4 Multivariate analysis of different parameters for
overall survival
Characteristic Hazard Ratio 95% CI P
cyclinD1 0.75 0.26-2.12 0.591
h-prune 2.37 0.85-7.03 0.078
pERK1-2 1.08 0.37-3.18 0.875
p53 0.74 0.34-1.58 0.443
survivin 3.40 1.20-4.76 0.012
estrogen receptor (ER) 1.88 0.57-6.91 0.281
progesterone receptor (PR) 1.33 0.36-4.84 0.639
proliferation index (Ki67) 1.81 0.48-6.85 0.377
HER2 3.24 0.96-14.5 0.059
pathological response 8.83 1.10-50.2 0.040
Stratified by age. CI, confidence interval. In bold, significant values.
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T4 patients, further large prospective studies are
awaited. Nevertheless, translational studies investigating
additional molecular biomarkers should contribute to
more accurately identify subsets of patients who would
be expected to be more or less likely to respond to spe-
cific therapeutic interventions.
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